Bass returns funds but vows to continue pharma fight

Hedge fund manager Kyle Bass has returned almost $700 million to investors that backed his inter partes review (IPR) challenges, but has vowed to continue challenging pharmaceutical patents after being given the green light to tackle another.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

PTAB accepts Bass’s toenail patent challenges

25 February 2016 The Coalition for Affordable Drugs and Anacor Pharmaceuticals will face off in a dispute over the validity of two anti-fungal patents after the Patent Trial and Appeal Board gave the go-ahead to two inter partes review petitions.

Americas

PTAB rejects Vimovo IPR trial

11 December 2015 The Patent Trial and Appeal Board has rejected the Coalition for Affordable Drugs' attempt to invalidate a patent covering Pozen’s Vimovo (naproxen and esomeprazole magnesium) drug.

Big Pharma

Celgene fends off Kyle Bass challenge

17 November 2015 Biopharmaceutical company Celgene has finally found success in fending off a challenge to one of its patents from Kyle Bass’s organisation the Coalition for Affordable Drugs.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Bass returns funds but vows to continue pharma fight

More on this story

Editor's picks

Editor's picks

More features